Vtama (tapinarof) is a topical treatment approved for plaque psoriasis in adults [1].
What is Vtama used for?
Vtama is indicated for the topical treatment of plaque psoriasis in adult patients [1].
How does Vtama work for psoriasis?
Vtama is an aryl hydrocarbon receptor (AhR) agonist. By activating AhR, it modulates inflammatory and immune responses that are involved in the development of psoriasis [1].
When was Vtama approved?
The U.S. Food and Drug Administration (FDA) approved Vtama in July 2022 [1].
What are the common side effects of Vtama?
Common side effects of Vtama include [1]:
* Application site reactions (like itching, burning, and stinging)
* Folliculitis (inflammation of hair follicles)
* Acne
What is the patent status of Vtama?
Information on the specific patents covering Vtama and their expiry dates can be found on DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent information for pharmaceutical products, which can be relevant for understanding market exclusivity and potential generic competition [2].
How does Vtama compare to other psoriasis treatments?
Vtama is a novel topical option with a mechanism of action distinct from some other topical treatments. It is applied once daily and does not carry the same type of warnings associated with other topical corticosteroids or vitamin D analogs [1].
Who makes Vtama?
Vtama is manufactured by Dermavant Pharmaceuticals [1].